About Acurx Pharmaceuticals Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://www.acurxpharma.com/
Frequently Asked Questions
What is the 52-week range for ACXP?
The 52-week high is $8.34 and the 52-week low is $1.23.
What is the P/E ratio for ACXP?
The P/E ratio data is currently unavailable.
What is the dividend yield for ACXP?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -124.74%.
What is the Net Profit Margin?
Net Margin data is currently unavailable.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 0.99.
Analyst Recommendation Trends
Wall Street analyst consensus for ACXP over the last few months:
Latest ACXP News
Acurx Pharmaceuticals Announces First Patient Enrolled in PATHFINDER Clinical Trial of Ibezapolstat in Multiply-Recurrent C. difficile Infection
Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, today announced that the first patient has been enrolled in its new clinical trial (PATHFINDER) in patients with multiply recurrent C. difficile Infection (rCDI). This new, fully funded,PATHFINDER clinical trial is a pilot trial in approximately 20 patients with multiply-recurrent CDI (at least three episo
HC Wainwright & Co. Reiterates Buy on Acurx Pharmaceuticals, Maintains $31 Price Target
HC Wainwright & Co. analyst Matthew Keller reiterates Acurx Pharmaceuticals (NASDAQ:ACXP) with a Buy and maintains $31 price target.
Acurx Pharmaceuticals Says First Patient Enrolled In New PATHFINDER Clinical Trial In Patients With Multiply Recurrent C. Difficile Infection
PATHFINDER is a ground-breaking Phase 2 clinical trial with ibezapolstat (IBZ) in patients with multiply-recurrent CDI (C. difficile Infection) (rCDI) that, together with results from the planned ASPIRE Phase 3 trial in
New to The Street Broadcasts Tonight at 6:30 PM ET Across the United States, Latin America and MENA, Featuring BioVie, Acurx Pharmaceuticals, Lantern Pharma and SafeSpace Global
BioVie (Nasdaq:BIVI) CEO Cuong Do Discusses the Company's Recent Long COVID Clinical Results and the Potential of Bezisterim to Address Significant Unmet Patient NeedsNEW YORK CITY, NY / ACCESS Newswire / September 19, 2026 / , one of the world's longest-running sponsored and syndicated business television programs, announces tonight's broadcast featuring executives from BioVie Inc. (Nasdaq:BIVI), Acurx Pharmaceuticals, Inc.
Transcript: Acurx Pharmaceuticals Q2 2026 Earnings Conference Call
Acurx Pharmaceuticals (NASDAQ:ACXP) reported second-quarter financial results on Friday. The transcript from the company's second-quarter earnings call has been provided below. Benzinga APIs provide real-time access
Acurx Announces Presentation of a Scientific Poster at the Premier International C. difficile Symposium (ICDS) Demonstrating Superior In Vitro Kill Kinetics of Ibezapolstat vs. Vancomycin and Fidaxomicin (Standards of Care) in Clostridioides difficile and Vancomycin-Resistant Enterococcus Co-Cultures
Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) a late clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that a scientific poster entitled: Comparative In Vitro Killing Kinetics of Ibezapolstat and Comparator Antibiotics in Clostridioides difficile and Vancomycin-resistant Enterococcus Co-Cultures was presented at the 9th International C. difficile Symposium held in Bled, Slovenia from September 8-10, 2026. The
Acurx Pharmaceuticals Files Prospectus For 1.5M Offering
-SEC Filing
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-04-20 | Sailer Carl | +2,150 | - | - |
| 2026-04-20 | Donohue James J. | +2,150 | - | - |
| 2026-04-20 | Shawah Robert G. | +25,900 | - | - |
| 2026-04-20 | DEAN JACK H | +2,150 | - | - |
| 2026-04-20 | Scodari Joseph C | +2,150 | - | - |
| 2026-04-20 | LUCI DAVID P | +37,100 | - | - |
| 2026-04-20 | HARRISON THOMAS L | +2,150 | - | - |
| 2026-04-20 | DELUCCIA ROBERT J | +37,100 | - | - |